ADMA BIOLOGICS, INC. Insider Trading Arrangements
Rule 10b5-1 and other trading arrangements that directors and officers adopted or terminated, as each 10-Q and 10-K tags them (Item 408(a)), newest report first.
- 2026-02-25: Individual Adam Grossman; Title President and CEO; Arrangement Rule 10b5-1; Adopted November 14, 2025.
- 2025-03-18: Individual Adam Grossman; Title President and CEO; Arrangement Rule 10b5-1; Adopted December 5, 2024.
| Report filed | Individual | Title | Arrangement | Adopted | Terminated | Expires or duration | Securities covered |
|---|---|---|---|---|---|---|---|
| 2026-02-25 10-K | Adam Grossman | President and CEO | Rule 10b5-1 | November 14, 2025 | December 31, 2026 P412D | ||
| 2025-03-18 10-K | Adam Grossman | President and CEO | Rule 10b5-1 | December 5, 2024 | December 31, 2025 P391D |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |